Description：Enzyme Immunoassay for quantitative detection of Palivizumab in serum and plasma..
Palivizumab is a humanized monoclonal antibody （IgG） directed against an epitope in the A antigenic site of the F protein of RSV.
It is used in the prevention of respiratory syncytial virus （RSV） infections.
It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease.
Krishgen PK kits, developed using the innovator drug as calibrator, are used for the quantitation of serum protein drug levels, and can be used for biosimilar and generics research as well.
About the kit：
- Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
- Recovery rates are between 85 - 115％
- Ready to use with a standard protocol with break-apart pre-coated wells
- Validated as per US FDA guidelines for Bioassays
- Optimized for matrix effects to ensure higher sensitivity.
- Shelf life： 1 year
The method employs the quantitative enzyme immunoassay technique.
Standards or samples are pipetted into microwells pre-coated with Anti- Palivizumab antibody and Palivizumab present in the sample and standards are bound by Anti- Palivizumab antibody.
In the second step, Detection antidody is added and incubated.
In the third step, a HRP conjugate is pipetted and incubated.
Free HRP conjugate will be removed by washing.
Addition of TMB substrate will develop blue color and intensity of blue colour in wells is proportional to the concentration of Palivizumab present in standard or sample.
Color development is then stopped by addition of stop solution.
